Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Glucotrack (GCTK) Gains from Investment Securities (2016 - 2019)

Glucotrack's Gains from Investment Securities history spans 6 years, with the latest figure at $156.0 million for Q4 2019.

  • For the quarter ending Q4 2019, Gains from Investment Securities rose 38912.28% year-over-year to $156.0 million, compared with a TTM value of $156.0 million through Dec 2019, up 105237.54%, and an annual FY2024 reading of $79000.0, changed N/A over the prior year.
  • Gains from Investment Securities for Q4 2019 was $156.0 million at Glucotrack, up from $399892.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $156.0 million in Q4 2019, with the low at -$321575.0 in Q3 2016.
  • Average Gains from Investment Securities over 5 years is $9.9 million, with a median of -$35674.5 recorded in 2015.
  • Year-over-year, Gains from Investment Securities plummeted 1055.12% in 2016 and then surged 38912.28% in 2019.
  • Tracing GCTK's Gains from Investment Securities over 5 years: stood at -$27839.0 in 2015, then soared by 2121.64% to $562803.0 in 2016, then skyrocketed by 109.98% to $1.2 million in 2017, then tumbled by 66.16% to $399892.0 in 2018, then surged by 38912.28% to $156.0 million in 2019.
  • Per Business Quant, the three most recent readings for GCTK's Gains from Investment Securities are $156.0 million (Q4 2019), $399892.0 (Q4 2018), and -$91762.0 (Q3 2018).